Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Field is an analyst with an average return of -2.1% and a 37.76% success rate. Field covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, AstraZeneca, and Roche Holding AG.
In addition to Barclays, GlaxoSmithKline also received a Hold from Deutsche Bank 's Emmanuel Papadakis in a report issued yesterday. However, on June 30, J.P. Morgan maintained a Sell rating on GlaxoSmithKline (LSE: GSK).
Based on GlaxoSmithKline's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of p7.52 billion and a net profit of p1.62 billion. In comparison, last year the company earned a revenue of p7.36 billion and had a net profit of p1.05 billion
Based on the recent corporate insider activity of 311 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GSK in relation to earlier this year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
BP Earnings Call: Strong Gains Amid Challenges
BP plc. ((BP)) has held its Q2 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. BP's Earnings Call Reflects Strong Performance Amid Challenges BP's recent earnings call conveyed a generally positive sentiment, underscored by robust operational performance and significant exploration successes. The company reported increased earnings, successful divestments, cost reductions, and enhanced shareholder returns. However, challenges persist in certain segments, such as tight diesel margins and impairments in specific areas. Strong Upstream Performance BP showcased its strong upstream performance by bringing five new major oil and gas projects online and sanctioning four additional ones. The company also celebrated ten exploration discoveries, marking a remarkable year for discoveries, with the Bumerangue Block in Brazil standing out despite concerns over CO2 content. Increase in Underlying Earnings The earnings call highlighted a substantial increase in underlying earnings within BP's customers' business, which rose by approximately 50% compared to the previous year. This growth occurred despite challenging market conditions, showcasing BP's resilience and strategic prowess. Successful Divestments and Cost Reductions BP reported successful divestments, with expected proceeds reaching around $3 billion for the year. Additionally, the company achieved structural cost reductions of approximately $1.7 billion since early 2024, demonstrating its commitment to financial efficiency. Dividend Increase and Share Buyback Shareholders were pleased with BP's announcement of a dividend increase of 4% to $0.0832 per ordinary share. Furthermore, the company declared a $750 million share buyback for the second quarter, reinforcing its commitment to returning value to shareholders. Record Refining Availability BP achieved record refining availability of 96.4% for the quarter, the highest since 2006. This milestone reflects the company's operational excellence and ability to maintain high levels of efficiency. Challenging Diesel Margins Despite the positive developments, BP faced challenges with tight diesel margins in its TravelCenters of America business, which impacted profitability. This segment remains an area of concern for the company. Impairments in Customer and Products and Gas and Low Carbon Segments BP took several impairments related to decisions on hydrogen and biofuels projects in Australia, as well as in the gas and low carbon space concerning M&S. These impairments highlight the ongoing challenges in these segments. Forward-Looking Guidance Looking ahead, BP's guidance remains optimistic, with operational reliability reported at over 96% across both upstream and downstream sectors. The company is committed to its 12-quarter strategic plan, focusing on enhancing operational efficiency and shareholder value. BP aims to continue its momentum with new projects and exploration discoveries, despite the challenges in certain areas. In conclusion, BP's earnings call painted a picture of a company achieving strong operational and financial performance, while also navigating challenges in specific segments. The overall sentiment was positive, with significant achievements in exploration and shareholder returns, although certain areas require continued attention and improvement.
Globe and Mail
2 hours ago
- Globe and Mail
Chronic Lymphocytic Leukemia Pipeline Outlook Report 2025: Key 55+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Chronic Lymphocytic Leukemia Pipeline Insight 2025' report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline landscape. It covers the Chronic Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Chronic Lymphocytic Leukemia Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Chronic Lymphocytic Leukemia Pipeline Outlook Report In July 2025, AstraZeneca announced a Phase IV study to evaluate the safety and tolerability of acalabrutinib (monotherapy, 100 mg orally [po], twice daily [bd]) compared to investigator's choice of treatment, in patients with CLL (TN or R/R) and moderate to severe cardiac impairment. All patients will have cardiac impairment as defined by LVEF of < 50%. In July 2025, BeiGene announced a study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated CLL. This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax. In July 2025, AbbVie conducted a study doctors put the participants in 1 of 4 groups, called treatment arms. Participants will receive oral venetoclax in combination with intravenously (IV) infused obinutuzumab or oral acalabrutinib at in different dosing schemes as part of treatment. Approximately 120 adult participants with CLL who are being treated with venetoclax will be enrolled in the study in approximately 80 sites worldwide. DelveInsight's Chronic Lymphocytic Leukemia pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Chronic Lymphocytic Leukemia treatment. The leading Chronic Lymphocytic Leukemia Companies such as Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others. Promising Chronic Lymphocytic Leukemia Therapies such as Obinutuzumab, Rituximab, Chlorambucil, Acalabrutinib, and others. Discover how the Chronic Lymphocytic Leukemia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Chronic Lymphocytic Leukemia Clinical Trials and Studies Chronic Lymphocytic Leukemia Emerging Drugs Profile Pirtobrutinib: Loxo Oncology Pirtobrutinib is an investigational, oral, highly-selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor, signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. The drug is currently being evaluated in Phase III stage of development for the treatment of chronic lymphocytic leukemia. Cirmtuzumab: Oncternal Therapeutics Cirmtuzumab is a first-in-class humanized monoclonal antibody that binds with high affinity to a biologically important epitope on ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1). ROR1 is a type 1 transmembrane protein, essential for fetal development that is expressed on the plasma membrane with an extracellular domain that is essential for ligand binding and signal transduction. Cirmtuzumab binds to many different types of cancer cells but does not recognize most normal adult tissues. Cirmtuzumab was developed at the University of California in San Diego based on the pioneering scientific research of Thomas Kipps, MD, Ph.D., and his colleagues at the Moores Cancer Center. Oncternal holds an exclusive worldwide license to develop and commercialize antibodies recognizing ROR1. The development of cirmtuzumab has been supported by the California Institute for Regenerative Medicine (CIRM), in recognition of the role of ROR1 in conferring stem cell-like properties to the cancer cells that express it. A Phase II clinical trial is evaluating Cirmtuzumab to treat CLL. MS-553: MingSight Pharmaceuticals MS-553 is a potent, highly selective, oral, non-covalent inhibitor of PKCβ, a signaling molecule immediately downstream of BTK and PLCγ2 in the B-cell receptor (BCR) pathway. As PKCβ is downstream of both BTK and PLCγ2, it has the potential to treat acquired BTK resistance mutations in either protein, a feature absent from many second-generation BTK inhibitors. In the preliminary results, MS-553 was generally well tolerated, with initial anti-tumor activity seen in the heavily pretreated population. Potent to full inhibition of PKCβ signaling over 24 hours of exposure has been demonstrated. Additional dosing of patients will be completed to further assess MS-553 efficacy in patients with acquired resistance mutations in BTK and PLCG2. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of CLL. NX-2127: Nurix Therapeutics NX-2127 is an oral small molecule that combines the activity of a targeted BTK degrader with the cereblon immunomodulatory activity of an IKZF degrader. Cereblon immunomodulatory drugs that induce degradation are IKZF1 and IKZF3. Preclinical data support the activity of NX-2127 in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance to FDA-approved agents. Studies in non-human primates confirm potent BTK degradation with once-daily oral dosing. NX-2127 is being tested in an ongoing Phase I trial for patients with chronic lymphocytic leukemia who have failed prior treatments. NX-5948: Nurix Therapeutics NX-5948 is an oral small molecule degrader of BTK. Preclinical data support the activity of NX-5948 in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance to leading FDA approved agents. NX-5948 lacks cereblon immunomodulatory activity and has demonstrated the ability to cross the blood-brain barrier in animal models. NX-5948 has also demonstrated activity in animal models of autoimmune disease. The drug is currently being evaluated in the Phase I stage of development for the treatment of chronic lymphocytic leukemia. The Chronic Lymphocytic Leukemia Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Lymphocytic Leukemia with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Lymphocytic Leukemia Treatment. Chronic Lymphocytic Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Chronic Lymphocytic Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Lymphocytic Leukemia market Explore groundbreaking therapies and clinical trials in the Chronic Lymphocytic Leukemia Pipeline. Access DelveInsight's detailed report now! @ New Chronic Lymphocytic Leukemia Drugs Chronic Lymphocytic Leukemia Companies Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others. Chronic lymphocytic leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Chronic Lymphocytic Leukemia Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Chronic Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspectives Scope of the Chronic Lymphocytic Leukemia Pipeline Report Coverage- Global Chronic Lymphocytic Leukemia Companies- Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others. Chronic Lymphocytic Leukemia Therapies- Obinutuzumab, Rituximab, Chlorambucil, Acalabrutinib, and others. Chronic Lymphocytic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Chronic Lymphocytic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Chronic Lymphocytic Leukemia drug development? Find out in DelveInsight's exclusive Pipeline Report—access it now! @ Chronic Lymphocytic Leukemia Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Chronic lymphocytic leukemia: Overview Pipeline Therapeutics Therapeutic Assessment Chronic lymphocytic leukemia– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Pirtobrutinib: Loxo Oncology Drug profiles in the detailed report….. Mid Stage Products (Phase II) Cirmtuzumab: Oncternal Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) NX-2127: Nurix Therapeutics Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Chronic lymphocytic leukemia Key Companies Chronic lymphocytic leukemia Key Products Chronic lymphocytic leukemia- Unmet Needs Chronic lymphocytic leukemia- Market Drivers and Barriers Chronic lymphocytic leukemia- Future Perspectives and Conclusion Chronic lymphocytic leukemia Analyst Views Chronic lymphocytic leukemia Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
3 hours ago
- Globe and Mail
Why Novo Nordisk Stock Slipped Today
Key Points It was a double miss for the Wegovy maker in its second quarter. It's been hammered not only by competing licensed drugs, but it also has to contend with copycats. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest earnings release, comparing unfavorably to the modest (0.7%) gain of the S&P 500 index. Still growing, but... Novo Nordisk, famous for its Wegovy obesity drug (and its sibling, diabetes treatment Ozempic), unveiled its first half and second quarter of 2025 figures early Wednesday morning. For the quarter, the company booked 76.9 billion Danish kroner ($11.9 billion) in revenue, which was up only marginally on a sequential basis, and 13% higher compared to the same period of 2024. Net income, meanwhile, was down from the previous quarter but up from the year-ago quarter. It rose by 32% year over year to 26.5 billion kroner ($4.1 billion), or 5.96 kroner ($0.92) per share. Both headline numbers missed the consensus analyst estimates, although not by much. Pundits tracking the company were modeling the equivalent of just under $12 billion for revenue, and $0.95 per share on the bottom line. Although Novo Nordisk continues to post double-digit increases thanks largely to Wegovy and Ozempic, it has been in the investor doghouse so far this month. That's because at the end of July, it significantly cut its guidance for both total sales and operating profit. Withering competition Much of this has to do with the intense competition Novo Nordisk is facing due to the runaway success of those medications. These days, pharmacy sector powerhouse Eli Lilly is doing brisk business with a directly competing product, Zepbound, while third parties are copying Wegovy's semaglutide molecule for their own compounded products. The company announced no fewer than 14 new lawsuits on Tuesday, making a total of 146 across 40 U.S. states, to combat the latter. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $619,036!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,092,648!* Now, it's worth noting Stock Advisor's total average return is 1,026% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
